Primary antiphospholipid syndrome (PAPS) is a chronic autoimmune disorder clinically characterized by thromboembolic events or obstetric complications. Prolonged anticoagulation therapy with vitamin K antagonists (VKA) is the treatment of choice for PAPS patients with thrombosis. However, the efficacy of VKA therapy depends on laboratory monitoring, dose adjustment, adequate lifestyle and adherence to treatment. Difficulties with VKA therapy can affect patients’ self-perceived health related quality of life (HRQOL). This study aims to evaluate PAPS patients' HRQOL, therapy adherence and knowledge of treatment.
Methods
A general Medical Outcome Study Short Form-36 (SF-36) and the Duke Anticoagulation Satisfaction Scale (DASS) were used to access APS-patients self-perceived HRQOL. Treatment adherence was measured by the Treatment Measure Adhesion (TMA) – oral anticoagulant version instrument, and knowledge of VKA treatment was measured using the MedTake test.
Results
66 PAPS patients using VKA were assessed. 63% of them were female; the mean age was 41.9 years old, approximately 60% had unprovoked venous thrombosis and one third of the patients had recurrent thrombotic events. The most impacted domain of DASS was “psychological impacts” and the factors associated to anticoagulation related poor HRQOL were: female sex, presence of arterial thrombosis and INR lability. Using the SF-36 instrument, PAPS-patients self-perceived HRQOL was poorer than that of the general Brazilian population and was associated with female sex and presence of cardiovascular risk factors.
Conclusion
Despite the high adherence to treatment and knowledge of VKA therapy, self-perceived HRQOL is poor in patients with PAPS and is mainly affected by VKA therapy. Searching for better treatment options is warranted.
ChighizolaCBUbialiTMeroniPL.Treatment of thrombotic antiphospholipid syndrome: the rationale of current management—an insight into future approaches. J Immunol Res2015;
2015: 951424.
7.
EspinosaGCerveraR.Current treatment of antiphospholipid syndrome: lights and shadows. Nat Rev Rheumatol2015;
11: 586–596.
8.
CerveraRPietteJCFontJ, et al.; Euro-Phospholipid Project Group.
Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum2002;
46: 1019–1027.
9.
CerveraRSerranoRPons-EstelGJ, et al.;Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies).
Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis2015;
74: 1011–1018.
10.
CorbiISADantasRASPelegrinoFMCarvalhoARDS.Health related quality of life of patients undergoing oral anticoagulation therapy. Rev Lat Am Enfermagem2011;
19: 865–873.
11.
HirshJDalenJEDeykinDPollerLBusseyH.Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest1995;
108: 231S–246S.
12.
AlmeidaGDQNoblatLDACBPassosLCSdo NascimentoHF.Quality of life analysis of patients in chronic use of oral anticoagulant: an observational study. Health Qual Life Outcomes2011;
9: 91.
13.
CasaisPMeschengieserSSSanchez-LucerosALazzariMA.Patients’ perceptions regarding oral anticoagulation therapy and its effect on quality of life. Curr Med Res Opin2005;
21: 1085–1090.
14.
LimaMGBarrosMBCesarCLGoldbaumMCarandinaLCiconelliRM.Health related quality of life among the elderly: a population-based study using SF-36 survey. Cad Saude Publica2009;
25: 2159–2167.
15.
SeidlEMFZannonC.Qualidade de vida e saúde: aspectos conceituais e metodológicos. Cad Saude Publica2004;
20: 580–588.
16.
CarvalhoARdSDantasRASPelegrinoFMCorbiISA.Adaptation and validation of an oral anticoagulation measurement of treatment adherence instrument. Rev Lat Am Enfermagem2010;
18: 301–308.
17.
RaehlCLBondCAWoodsTPatryRASleeperRB.Individualized drug use assessment in the elderly. Pharmacotherapy2002;
22: 1239–1248.
18.
BolelaF.Estado de saúde e adesão ao tratamento de pacientes atendidos em ambulatório especializado em anticoagulação oral.
São Paulo:
Universidade de São Paulo, 2013.
19.
BonettiAFBagatimBQMendesAM, et al.
Impact of discharge medication counseling in the cardiology unit of a tertiary hospital in Brazil: a randomized controlled trial. Clinics2018;
73: e325.
20.
CorbiISA.Efeitos de um programa educativo na qualidade de vida relacionada à saúde e na adesão à terapia de anticoagulação oral: estudo clínico randomizado.
São Paulo:
Universidade de São Paulo, 2013.
21.
DewulfNLSdos SantosVPereiraLRLde Almeida TronconLE.Beneficial effects of a pharmaceutical care program on outpatients with inflammatory bowel disease. J Basic Appl Pharmaceut Sci2017;
38: 10.
22.
PeresHAPereiraLRLMartinezEZVianaCMFoss-FreitasMC.Heart failure is associated with non-adherence to pharmacotherapy in elderly with type 2 diabetes mellitus in public health system Brazilians. Diabetes Metab Syndr2019;
13: 939–946.
23.
AlbaPGómez-PuertaJAGoycochea-RoblesMVAmigoMC.Organ damage and quality of life in antiphospholipid syndrome. Curr Rheumatol Rep2016;
18: 7.
24.
CiconelliRMFerrazMBSantosWMeinãoIQuaresmaMR.Tradução Para a língua Portuguesa e validação do questionário genérico de avaliação de qualidade de vida SF-36 (brasil SF-36). Rev Bras Reumatol1999;
39: 143–150.
25.
PelegrinoFM.Adaptação cultural e validação do instrumento duke anticoagulation satisfaction scale (DASS): versao Para brasileiros em uso de anticoagulação oral.
São Paulo: Universidade de São Paulo, 2009.
26.
LaguardiaJCamposMRTravassosCNajarALAnjosLADVasconcellosMM.Brazilian normative data for the short form 36 questionnaire, version 2. Rev Bras Epidemiol2013;
16: 889–897.
27.
DalpiazJColetCPetriAAmadorTAHeineckI.Quality of life of warfarin users treated at the public health system. Journal of Epidemiology and Infection Control2017;
7: 8.
28.
ElewaHFAbdelSamadOElmubarkAE, et al.
The first pharmacist-managed anticoagulation clinic under a collaborative practice agreement in Qatar: clinical and patient-oriented outcomes. J Clin Pharm Ther2016;
41: 403–408.
29.
CarvalhoARdSCiolMATiuFRossiLADantasRAS.Oral anticoagulation: the impact of the therapy in health-related quality of life at six-month follow-up. Rev Latino-Am Enfermagem2013;
21: 105–112.
30.
Silva de AssisMCNascimento CruzLZuchinaliPRohdeLERejane RabeloE.Does treatment guided by vitamin K in the diet alter the quality of life of anticoagulated patients?Nutricion Hospitalaria2012;
27: 1328–1333.
31.
ZuilySRatA-CRegnaultV, et al.; TAC(I)T Investigators.
Impairment of quality of life in patients with antiphospholipid syndrome. Lupus2015;
24: 1161–1168.
32.
Dall’AraFReggiaRTaraborelliM, et al.
Patients with longstanding primary antiphospholipid syndrome: retrospective analysis of organ damage and mortality. Lupus2014;
23: 1255–1258.
33.
TaraborelliMReggiaRDall’AraF, et al.
Longterm outcome of patients with primary antiphospholipid syndrome: a retrospective multicenter study. J Rheumatol2017;
44: 1165–1172.
34.
GeorgopoulouSEfraimidouSMacLennanSJIbrahimFCoxT.Antiphospholipid (hughes) syndrome: description of population and health-related quality of life (HRQoL) using the SF-36. Lupus2015;
24: 174–179.
35.
GeorgopoulouSEfraimidouSMacLennanSJIbrahimFCoxT.The relationship between social support and health-related quality of life in patients with antiphospholipid (Hughes) syndrome. Modern Rheumatol2018;
28: 147–155.
36.
ChambersBAGuoSSSiervogelRHallGChumleaWC.Cumulative effects of cardiovascular disease risk factors on quality of life. J Nutr Health Aging2002;
6: 179–184.
37.
da Silva SaraivaSOrsiFASantosMP, et al.
Home management of INR in the public health system: feasibility of self-management of oral anticoagulation and long-term performance of individual POC devices in determining INR. J Thromb Thrombolysis2016;
42: 146–153.
38.
HambletonJ.Home monitoring of anticoagulation. J Thromb Thrombolysis2003;
16: 39–42.
39.
HeneghanCJGarcia-AlaminoJMSpencerEA, et al.
Self-monitoring and self-management of oral anticoagulation. Cochrane Database Syst Rev2016;
7: CD003839.
40.
MoneyAGBarnettJKuljisJDuffinD.Patient perceptions and expectations of an anticoagulation service: a quantitative comparison study of clinic-based testers and patient self-testers. Scand J Caring Sci2015;
29: 662–678.
41.
PerrySLSamsaGPOrtelTL.Point-of-care testing of the international normalized ratio in patients with antiphospholipid antibodies. Thromb Haemost2005;
94: 1196–1202.
42.
WahlDDufrostV.Direct oral anticoagulants in antiphospholipid syndrome: too early or too late?Ann Intern Med2019;
171: 765–766.
43.
DufrostVRisseJReshetnyakT, et al.
Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis. Autoimmun Rev2018;
17: 1011–1021.
44.
Ordi-RosJSáez-CometLPérez-ConesaM, et al.
Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial. Ann Intern Med2019;
171: 685–694.
45.
PengoVDenasGZoppellaroG, et al.
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood2018;
132: 1365–1371.
